Phase II Study of RT Concurrent w/ Cetuximab in Patients w/ Locally Advanced Head and Neck SCC Who Do Not Qualify For Standard Chemotherapy Due To Age >70 Or Co-Morbidities.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 24 Feb 2021 Biomarkers information updated
- 29 May 2009 New trial record